Lupus Nephritis Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. Symptoms include weight gain, high blood pressure, dark urine and foamy, frothy urine. Treatment includes corticosteroids, immunosuppressive drugs and health lifestyle.
Request for sample @ https://marketreportscenter.com/request-sample/438516
Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Check Discount on report @ https://marketreportscenter.com/request-discount/438516
latest report Lupus Nephritis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.
The report is built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438516/lupus-nephritis-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center